Percutaneous coronary intervention (PCI): Difference between revisions

Jump to navigation Jump to search
← Older edit
VisualWikitext
Smitakohli (talk | contribs)
284 edits
No edit summary
Vendhan Ramanujam (talk | contribs)
nocaptcha
2,096 edits
 
(241 intermediate revisions by 7 users not shown)
Line 1: Line 1:
{{SI}}
#redirect[[Percutaneous coronary intervention: basic principles and guidelines]]
{{WikiDoc Cardiology Network Infobox}}
{{CMG}}
 
{{Editor Help}}
 
== Epidemiology and Demographics ==
* Approximately 850,000 PCIs are performed each year in the United States.
 
==Imaging Studies During PCI==
'''Intravascular Ultrasound Imaging'''
* ''Class IIa''
IVUS is reasonable for the following: a. Assessment of the adequacy of deployment of coronary stents, including the extent of stent apposition
and determination of the minimum luminal diameter
within the stent. (Level of Evidence: B)
b. Determination of the mechanism of stent restenosis
(inadequate expansion versus neointimal proliferation)
and to enable selection of appropriate therapy
(vascular brachytherapy versus repeat balloon
expansion). (Level of Evidence: B)
c. Evaluation of coronary obstruction at a location
difficult to image by angiography in a patient with
a suspected flow-limiting stenosis. (Level of
Evidence: C)
d. Assessment of a suboptimal angiographic result
after PCI. (Level of Evidence: C)
e. Establishment of the presence and distribution of
coronary calcium in patients for whom adjunctive
rotational atherectomy is contemplated. (Level of
Evidence: C)
f. Determination of plaque location and circumferential
distribution for guidance of directional coronary
atherectomy. (Level of Evidence: B)
* ''Class IIb''
IVUS may be considered for the following:
a. Determination of the extent of atherosclerosis in
patients with characteristic anginal symptoms and
a positive functional study with no focal stenoses or
mild CAD on angiography. (Level of Evidence: C)
b. Preinterventional assessment of lesional characteristics
and vessel dimensions as a means to select an
optimal revascularization device. (Level of Evidence: C)
c. Diagnosis of coronary disease after cardiac transplantation.
(Level of Evidence: C)
* ''Class III''
IVUS is not recommended when the angiographic
diagnosis is clear and no interventional treatment is
planned. (Level of Evidence: C)
 
== Other Diagnostic Studies ==
'''Coronary Artery Pressure and Flow: Use of Fractional Flow Reserve and Coronary Vasodilatory Reserve'''<ref>[http://content.onlinejacc.org/cgi/content/full/j.jacc.2009.10.015]</ref>
 
* ''Class IIa''
Coronary pressure (fractional flow reserve [FFR]) or Doppler
velocimetry can be useful to determine whether PCI of a
specific coronary lesion is warranted. FFR or Doppler
velocimetry can also be useful as an alternative to
performing noninvasive functional testing (e.g., when the
functional study is absent or ambiguous) to determine
whether an intervention is warranted. It is reasonable to
use intracoronary physiological measurements (coronary
pressure (FFR) (Level of Evidence: A) or
Doppler velocimetry (Level of Evidence: C)) in the
assessment of the effects of intermediate coronary
stenoses (30% to 70% luminal narrowing) in patients with
anginal symptoms.
* ''Class IIb''
1. Intracoronary physiologic measurements may be considered
for the evaluation of the success of PCI in
restoring flow reserve and to predict the risk of
restenosis. (Level of Evidence: C)
2. Intracoronary physiologic measurements may be considered
for the evaluation of patients with anginal
symptoms without an apparent angiographic culprit
lesion. (Level of Evidence: C)
* ''Class III''
Routine assessment with intracoronary physiological
measurements such as coronary pressure (FFR) or Doppler
ultrasound to assess the severity of angiographic disease in
concordant vascular distribution in patients with angina and
a positive, unequivocal noninvasive functional study is not
recommended. (Level of Evidence: C)
 
== Treatment ==
Any recommendations found on these pages are for education use only.  wiki doc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In recommending therapies, wiki doc suggests that the following classification scheme be used. This is the classification scheme used by the ACC / AHA Guidelines Committee.
Use the '''Class''' designation to indicate whether the therapy is recommended or not and the certainty surrounding that recommendation. Use the '''Level of Evidence''' designation to indicate the strength of the data associated with that recommendation.
 
== Classification of Recommendations ==
* Class I: Conditions for which there is evidence and/or general agreement that a given procedure or treatment is beneficial, useful, and effective.
 
* Class II: Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.
 
* Class IIa: Weight of evidence/opinion is in favor of usefulness/efficacy.
 
* Class IIb: Usefulness/efficacy is less well established by evidence/opinion.
 
* Class III: Conditions for which there is evidence and/or general agreement that a procedure/treatment is not useful/effective and in some cases may be harmful.
 
== Level of Evidence ==
* Level of Evidence A: Data derived from multiple randomized clinical trials or meta-analyses.
* Level of Evidence B: Data derived from a single randomized trial, or nonrandomized studies.
* Level of Evidence C: Only consensus opinion of experts,case studies, or standard-of-care.
 
wiki doc cites here the ACC / AHA Guidelines Based Therapy for ST Elevation MI.  '''DO NOT EDIT THESE GUIDELINES'''.  You can make comments regarding the guidelines in the discussion section.
 
==Institutional and Operator Competency==
===Quality Assurance===
* ''Class I''
1. An institution that performs PCI should establish an
ongoing mechanism for valid peer review of its quality
and outcomes. Review should be conducted both at
the level of the entire program and at the level of the
individual practitioner. Quality-assessment reviews
should take risk adjustment, statistical power, and
national benchmark statistics into consideration.
Quality-assessment reviews should include both tabulation
of adverse event rates for comparison with
benchmark values and case review of complicated
procedures and some uncomplicated procedures.
(Level of Evidence: C)
2. An institution that performs PCI should participate in
a recognized PCI data registry for the purpose of
benchmarking its outcomes against current national
norms. (Level of Evidence: C)
 
===Operator and Institutional Volume===
* ''Class I''
1. Elective PCI should be performed by operators with
acceptable annual volume (at least 75 procedures) at
high-volume centers (more than 400 procedures) with
onsite cardiac surgery (310,312). (Level of Evidence:
B)
2. Elective PCI should be performed by operators and
institutions whose historical and current risk-adjusted
outcomes statistics are comparable to those reported
in contemporary national data registries. (Level of
Evidence: C)
3. Primary PCI for STEMI should be performed by
experienced operators who perform more than 75
elective PCI procedures per year and, ideally, at least
11 PCI procedures for STEMI per year. Ideally, these
procedures should be performed in institutions that
perform more than 400 elective PCIs per year and
more than 36 primary PCI procedures for STEMI per
year. (Level of Evidence B)
* ''Class IIa''
1. It is reasonable that operators with acceptable volume
(at least 75 PCI procedures per year) perform PCI at
low-volume centers (200 to 400 PCI procedures per
year) with onsite cardiac surgery (310,312). (Level of
Evidence: B)
2. It is reasonable that low-volume operators (fewer than
75 PCI procedures per year) perform PCI at high-volume
centers (more than 400 PCI procedures per year)
with onsite cardiac surgery (310,312). Ideally, operators
with an annual procedure volume less than 75
should only work at institutions with an activity level
of more than 600 procedures per year. Operators who
perform fewer than 75 procedures per year should
develop a defined mentoring relationship with a highly
experienced operator who has an annual procedural
volume of at least 150 procedures per year. (Level of
Evidence: B)
* ''Class IIb''
The benefit of primary PCI for STEMI patients eligible
for fibrinolysis when performed by an operator
who performs fewer than 75 procedures per year (or
fewer than 11 PCIs for STEMI per year) is not well
established. (Level of Evidence: C)
* ''Class III''
It is not recommended that elective PCI be performed
by low-volume operators (fewer than 75 procedures
per year) at low-volume centers (200 to 400) with or
without onsite cardiac surgery (310,312). An institution
with a volume of fewer than 200 procedures per
year, unless in a region that is underserved because of
geography, should carefully consider whether it
should continue to offer this service. (Level of
Evidence: B)
 
===Role of Onsite Surgical Backup===
* ''Class I''
1. Elective PCI should be performed by operators with
acceptable annual volume (at least 75 procedures per
year) at high-volume centers (more than 400 procedures
annually) that provide immediately available
onsite emergency cardiac surgical services. (Level of
Evidence: B)
2. Primary PCI for patients with STEMI should be performed
in facilities with onsite cardiac surgery. (Level
of Evidence: B)
* ''Class III''
Elective PCI should not be performed at institutions
that do not provide onsite cardiac surgery. (Level of
Evidence: C)*
 
===Primary PCI for STEMI Without Onsite Cardiac Surgery===
* ''Class IIb''
Primary PCI for patients with STEMI might be considered
in hospitals without onsite cardiac surgery,
provided that appropriate planning for program
development has been accomplished, including appropriately
experienced physician operators (more than
75 total PCIs and, ideally, at least 11 primary PCIs per
year for STEMI), an experienced catheterization team
on a 24 hours per day, 7 days per week call schedule,
and a well-equipped catheterization laboratory with
digital imaging equipment, a full array of interventional
equipment, and intra-aortic balloon pump
capability, and provided that there is a proven plan
for rapid transport to a cardiac surgery operating
room in a nearby hospital with appropriate hemodynamic
support capability for transfer. The procedure
should be limited to patients with STEMI or MI with
new or presumably new left bundle-branch block on
ECG and should be performed in a timely fashion
(goal of balloon inflation within 90 minutes of presentation)
by persons skilled in the procedure (at least 75
PCIs per year) and at hospitals performing a minimum
of 36 primary PCI procedures per year. (Level of
Evidence: B)
* ''Class III''
Primary PCI should not be performed in hospitals
without onsite cardiac surgery and without a proven
plan for rapid transport to a cardiac surgery operating
room in a nearby hospital or without appropriate
hemodynamic support capability for transfer. (Level
of Evidence: C)
 
===Elective PCI Without Onsite Surgery===
* ''Class III''
Elective PCI should not be performed at institutions
that do not provide onsite cardiac surgery. (Level of
Evidence: C)*
 
===Patients With Asymptomatic Ischemia or CCS Class I or II Angina===
* ''Class IIa''
1. PCI is reasonable in patients with asymptomatic
ischemia or CCS class I or II angina and with 1 or
more significant lesions in 1 or 2 coronary arteries
suitable for PCI with a high likelihood of success and
a low risk of morbidity and mortality. The vessels to
be dilated must subtend a moderate to large area of
viable myocardium or be associated with a moderate
to severe degree of ischemia on noninvasive testing.
(Level of Evidence: B)
2. PCI is reasonable for patients with asymptomatic
ischemia or CCS class I or II angina, and recurrent
stenosis after PCI with a large area of viable
myocardium or high-risk criteria on noninvasive testing.
(Level of Evidence: C)
3. Use of PCI is reasonable in patients with asymptomatic
ischemia or CCS class I or II angina with significant
left main CAD (greater than 50% diameter
stenosis) who are candidates for revascularization but
are not eligible for CABG. (Level of Evidence: B)
* ''Class IIb''
1. The effectiveness of PCI for patients with asymptomatic
ischemia or CCS class I or II angina who have
2- or 3-vessel disease with significant proximal LAD
CAD who are otherwise eligible for CABG with 1
arterial conduit and who have treated diabetes or
abnormal LV function is not well established. (Level of
Evidence: B)
2. PCI might be considered for patients with asymptomatic
ischemia or CCS class I or II angina with nonproximal
LAD CAD that subtends a moderate area of
viable myocardium and demonstrates ischemia on
noninvasive testing. (Level of Evidence: C)
* ''Class III''
PCI is not recommended in patients with asymptomatic
ischemia or CCS class I or II angina who do not
meet the criteria as listed under the class II recommendations
or who have 1 or more of the following:
a. Only a small area of viable myocardium at risk
(Level of Evidence: C)
b. No objective evidence of ischemia. (Level of
Evidence: C)
c. Lesions that have a low likelihood of successful
dilatation. (Level of Evidence: C)
d. Mild symptoms that are unlikely to be due to
myocardial ischemia. (Level of Evidence: C)
e. Factors associated with increased risk of morbidity
or mortality. (Level of Evidence: C)
f. Left main disease and eligibility for CABG. (Level
of Evidence: C)
g. Insignificant disease (less than 50% coronary
stenosis). (Level of Evidence: C)
 
===Patients With CCS Class III Angina===
* ''Class IIa''
1. It is reasonable that PCI be performed in patients
with CCS class III angina and single-vessel or multivessel
CAD who are undergoing medical therapy and
who have 1 or more significant lesions in 1 or more
coronary arteries suitable for PCI with a high likelihood
of success and low risk of morbidity or mortality.
(Level of Evidence: B)
2. It is reasonable that PCI be performed in patients
with CCS class III angina with single-vessel or multivessel
CAD who are undergoing medical therapy with
focal saphenous vein graft lesions or multiple stenoses
who are poor candidates for reoperative surgery.
(Level of Evidence: C)
3. Use of PCI is reasonable in patients with CCS class III
angina with significant left main CAD (greater than
50% diameter stenosis) who are candidates for revascularization
but are not eligible for CABG. (Level of
Evidence: B)
* ''Class IIb''
1. PCI may be considered in patients with CCS class III
angina with single-vessel or multivessel CAD who are
undergoing medical therapy and who have 1 or more
lesions to be dilated with a reduced likelihood of success.
(Level of Evidence: B)
2. PCI may be considered in patients with CCS class III
angina and no evidence of ischemia on noninvasive
testing or who are undergoing medical therapy and
have 2- or 3-vessel CAD with significant proximal
LAD CAD and treated diabetes or abnormal LV function.
(Level of Evidence: B)
* ''Class III''
PCI is not recommended for patients with CCS class
III angina with single-vessel or multivessel CAD, no
evidence of myocardial injury or ischemia on objective
testing, and no trial of medical therapy, or who
have 1 of the following:
a. Only a small area of myocardium at risk. (Level of
Evidence: C)
b. All lesions or the culprit lesion to be dilated with
morphology that conveys a low likelihood of success.
(Level of Evidence: C)
c. Ahigh risk of procedure-related morbidity or mortality.
(Level of Evidence: C)
d. Insignificant disease (less than 50% coronary
stenosis). (Level of Evidence: C)
e. Significant left main CAD and candidacy for
CABG. (Level of Evidence: C)
 
===Patients With UA/NSTEMI===
* ''Class I''
An early invasive PCI strategy is indicated for
patients with UA/NSTEMI who have no serious
comorbidity and coronary lesions amenable to PCI.
Patients must have any of the following high-risk features:
a. Recurrent ischemia despite intensive anti-ischemic therapy. (Level of Evidence: A)
b. Elevated troponin level. (Level of Evidence: A)
c. New ST-segment depression. (Level of Evidence: A)
d. HF symptoms or new or worsening MR. (Level of Evidence: A)
e. Depressed LV systolic function. (Level of Evidence: A)
f. Hemodynamic instability. (Level of Evidence: A)
g. Sustained ventricular tachycardia. (Level of Evidence: A)
h. PCI within 6 months. (Level of Evidence: A)
i. Prior CABG. (Level of Evidence: A)
* ''Class IIa''
1. It is reasonable that PCI be performed in patients
with UA/NSTEMI and single-vessel or multivessel
CAD who are undergoing medical therapy with focal
saphenous vein graft lesions or multiple stenoses who
are poor candidates for reoperative surgery. (Level of Evidence: C)
2. In the absence of high-risk features associated with
UA/NSTEMI, it is reasonable to perform PCI in
patients with amenable lesions and no contraindication
for PCI with either an early invasive or early
conservative strategy. (Level of Evidence: B)
3. Use of PCI is reasonable in patients with UA/NSTEMI
with significant left main CAD (greater than 50%
diameter stenosis) who are candidates for revascularization
but are not eligible for CABG. (Level of Evidence: B)
* ''Class IIb''
1. In the absence of high-risk features associated with
UA/NSTEMI, PCI may be considered in patients with
single-vessel or multivessel CAD who are undergoing
medical therapy and who have 1 or more lesions to be
dilated with reduced likelihood of success. (Level of Evidence: B)
2. PCI may be considered in patients with UA/NSTEMI
who are undergoing medical therapy who have 2- or
3-vessel disease, significant proximal LAD CAD, and
treated diabetes or abnormal LV function. (Level of Evidence: B)
* ''Class III''
In the absence of high-risk features associated with
UA/NSTEMI, PCI is not recommended for patients
with UA/NSTEMI who have single-vessel or multivessel
CAD and no trial of medical therapy, or who
have 1 or more of the following:
a. Only a small area of myocardium at risk. (Level of Evidence: C)
b. All lesions or the culprit lesion to be dilated with
morphology that conveys a low likelihood of success. (Level of Evidence: C)
c. A high risk of procedure-related morbidity or mortality. (Level of Evidence: C)
d. Insignificant disease (less than 50% coronary stenosis). (Level of Evidence: C)
e. Significant left main CAD and candidacy for CABG. (Level of Evidence: B)
 
===Patients With STEMI: General and Specific Considerations===
* ''Class I''
===General considerations===
1. If immediately available, primary PCI should be performed
in patients with STEMI (including true posterior
MI) or MI with new or presumably new left bundle-
branch block who can undergo PCI of the infarct
artery within 12 hours of symptom onset, if performed
in a timely fashion (balloon inflation goal
within 90 minutes of presentation) by persons skilled
in the procedure (individuals who perform more than
75 PCI procedures per year, ideally at least 11 PCIs
per year for STEMI). The procedure should be supported
by experienced personnel in an appropriate
laboratory environment (one that performs more than
200 PCI procedures per year, of which at least 36 are
primary PCI for STEMI, and that has cardiac surgery
capability). (Level of Evidence: A) Primary PCI
should be performed as quickly as possible, with a
goal of a medical contact-to-balloon or door-to-balloon
time within 90 minutes. (Level of Evidence: B)
 
===Specific Considerations===
2. Primary PCI should be performed for patients less
than 75 years old with ST elevation or presumably
new left bundle-branch block who develop shock
within 36 hours of MI and are suitable for revascularization
that can be performed within 18 hours of shock, unless further support is futile because of the patient’s wishes or contraindications/unsuitability for further invasive care. (Level of Evidence: A)
3. Primary PCI should be performed in patients with severe congestive heart failure and/or pulmonary edema (Killip class 3) and onset of symptoms within 12 hours. The medical contact-to-balloon or door-to balloon time should be as short as possible (i.e., goal within 90 minutes). (Level of Evidence: B)
* ''Class IIa''
1. Primary PCI is reasonable for selected patients 75
years or older with ST elevation or left bundle-branch
block or who develop shock within 36 hours of MI and
are suitable for revascularization that can be performed
within 18 hours of shock. Patients with good
prior functional status who are suitable for revascularization
and agree to invasive care may be selected
for such an invasive strategy. (Level of Evidence: B)
2. It is reasonable to perform primary PCI for patients
with onset of symptoms within the prior 12 to 24
hours and 1 or more of the following:
a. Severe congestive heart failure (Level of Evidence: C)
b. Hemodynamic or electrical instability (Level of Evidence: C)
c. Evidence of persistent ischemia (Level of Evidence: C)
* ''Class IIb''
The benefit of primary PCI for STEMI patients eligible
for fibrinolysis when performed by an operator
who performs fewer than 75 PCI procedures per year
(or fewer than 11 PCIs for STEMI per year) is not well
established. (Level of Evidence: C)
* ''Class III''
1. Elective PCI should not be performed in a noninfarct-
related artery at the time of primary PCI of
the infarct related artery in patients without hemodynamic
compromise. (Level of Evidence: C)
2. Primary PCI should not be performed in asymptomatic
patients more than 12 hours after onset of STEMI who are hemodynamically and electrically
stable. (Level of Evidence: C)
 
===PCI in Fibrinolytic-Ineligible Patients===
* ''Class I''
Primary PCI should be performed in fibrinolytic-ineligible
patients who present with STEMI within 12
hours of symptom onset. (Level of Evidence: C)
* ''Class IIa''
It is reasonable to perform primary PCI for fibrinolytic-
ineligible patients with onset of symptoms
within the prior 12 to 24 hours and 1 or more of the
following:
a. Severe congestive heart failure. (Level of Evidence: C)
b. Hemodynamic or electrical instability. (Level of Evidence: C)
c. Evidence of persistent ischemia. (Level of Evidence: C)
 
===Facilitated PCI===
* ''Class IIb''
Facilitated PCI might be performed as a reperfusion
strategy in higher-risk patients when PCI is not immediately
available and bleeding risk is low. (Level of Evidence: B)
 
===PCI After Failed Fibrinolysis (Rescue PCI)===
* ''Class I''
1. Rescue PCI should be performed in patients less than
75 years old with ST elevation or left bundle-branch
block who develop shock within 36 hours of MI and
are suitable for revascularization that can be performed
within 18 hours of shock, unless further support
is futile because of the patient’s wishes or contraindications/
unsuitability for further invasive care.
(Level of Evidence: B)
2. Rescue PCI should be performed in patients with
severe congestive heart failure and/or pulmonary
edema (Killip class 3) and onset of symptoms within
12 hours. (Level of Evidence: B)
* ''Class IIa''
1. Rescue PCI is reasonable for selected patients 75
years or older with ST elevation or left bundle-branch
block or who develop shock within 36 hours of MI and
are suitable for revascularization that can be performed
within 18 hours of shock. Patients with good
prior functional status who are suitable for revascularization
and agree to invasive care may be selected
for such an invasive strategy. (Level of Evidence: B)
2. It is reasonable to perform rescue PCI for patients
with 1 or more of the following:
a. Hemodynamic or electrical instability. (Level of Evidence: C)
b. Evidence of persistent ischemia. (Level of Evidence: C)
* ''Class III''
Rescue PCI in the absence of 1 or more of the above
class I or IIa indications is not recommended. (Level of
Evidence: C)
 
===PCI After Successful Fibrinolysis or for Patients Not Undergoing Primary Reperfusion===
* ''Class I''
1. In patients whose anatomy is suitable, PCI should be
performed when there is objective evidence of recurrent
MI. (Level of Evidence: C)
2. In patients whose anatomy is suitable, PCI should be
performed for moderate or severe spontaneous or
provocable myocardial ischemia during recovery
from STEMI. (Level of Evidence: B)
3. In patients whose anatomy is suitable, PCI should be
performed for cardiogenic shock or hemodynamic
instability. (Level of Evidence: B)
* ''Class IIa''
1. It is reasonable to perform routine PCI in patients
with LV ejection fraction less than or equal to 0.40,
HF, or serious ventricular arrhythmias. (Level of Evidence: C)
2. It is reasonable to perform PCI when there is documented
clinical heart failure during the acute episode,
even though subsequent evaluation shows preserved
LV function (LV ejection fraction greater than 0.40). (Level of Evidence: C)
* ''Class IIb''
PCI might be considered as part of an invasive strategy
after fibrinolytic therapy. (Level of Evidence: C)
 
===PCI for Cardiogenic Shock===
* ''Class I''
Primary PCI is recommended for patients less than 75
years old with ST elevation or left bundle-branch
block who develop shock within 36 hours of MI and
are suitable for revascularization that can be performed
within 18 hours of shock, unless further support
is futile because of the patient’s wishes or contraindications/
unsuitability for further invasive care. (Level of Evidence: A)
* ''Class IIa''
Primary PCI is reasonable for selected patients 75
years or older with ST elevation or left bundle-branch
block who develop shock within 36 hours of MI and
are suitable for revascularization that can be performed
within 18 hours of shock. Patients with good prior functional status who are suitable for revascularization and agree to invasive care may be selected for such an invasive strategy. (Level of Evidence: B)
 
===Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery===
* ''Class I''
1. When technically feasible, PCI should be performed
in patients with early ischemia (usually within 30
days) after CABG. (Level of Evidence: B)
2. It is recommended that distal embolic protection
devices be used when technically feasible in patients
undergoing PCI to saphenous vein grafts. (Level of Evidence: B)
* ''Class IIa''
1. PCI is reasonable in patients with ischemia that
occurs 1 to 3 years after CABG and who have preserved
LV function with discrete lesions in graft conduits. (Level of Evidence: B)
2. PCI is reasonable in patients with disabling angina
secondary to new disease in a native coronary circulation
after CABG. (If angina is not typical, objective evidence of ischemia should be obtained.) (Level of Evidence: B)
3. PCI is reasonable in patients with diseased vein grafts
more than 3 years after CABG. (Level of Evidence: B)
4. PCI is reasonable when technically feasible in patients
with a patent left internal mammary artery graft who
have clinically significant obstructions in other vessels.
(Level of Evidence: C)
* ''Class III''
1. PCI is not recommended in patients with prior CABG
for chronic total vein graft occlusions. (Level of
Evidence: B)
2. PCI is not recommended in patients who have multiple
target lesions with prior CABGand who have multivessel
disease, failure of multiple SVGs, and
impaired LV function unless repeat CABG poses
excessive risk due to severe comorbid conditions. (Level of Evidence: B)
 
== Pharmacotherapy ==
 
'''Antiplatelet and Antithrombotic Adjunctive Therapies for PCI'''
 
==Oral Antiplatelet Therapy==
 
===Guidelines (DO NOT EDIT)===
* ''Class I''
1. Patients already taking daily chronic aspirin therapy
should take 75 to 325 mg of aspirin before the PCI
procedure is performed. (Level of Evidence: A)
2. Patients not already taking daily chronic aspirin therapy
should be given 300 to 325 mg of aspirin at least 2
hours and preferably 24 hours before the PCI procedure
is performed. (Level of Evidence: C)
3. After the PCI procedure, in patients with neither
aspirin resistance, allergy, nor increased risk of bleeding,
aspirin 325 mg daily should be given for at least 1
month after bare-metal stent implantation, 3 months
after sirolimus-eluting stent implantation, and 6
months after paclitaxel-eluting stent implantation,
after which daily chronic aspirin use should be continued
indefinitely at a dose of 75 to 162 mg. (Level of
Evidence: B)
4. A loading dose of clopidogrel should be administered
before PCI is performed. (Level of Evidence: A) An
oral loading dose of 300 mg, administered at least 6
hours before the procedure, has the best established
evidence of efficacy. (Level of Evidence: B)
5. In patients who have undergone PCI, clopidogrel 75
mg daily should be given for at least 1 month after
bare-metal stent implantation (unless the patient is at
increased risk of bleeding; then it should be given for
a minimum of 2 weeks), 3 months after sirolimus stent
implantation, and 6 months after paclitaxel stent
implantation, and ideally up to 12 months in patients
who are not at high risk of bleeding. (Level of
Evidence: B)
 
* ''Class IIa''
1. If clopidogrel is given at the time of procedure, supplementation
with GP IIb/IIIa receptor antagonists
can be beneficial to facilitate earlier platelet inhibition
than with clopidogrel alone. (Level of Evidence: B)
2. For patients with an absolute contraindication to
aspirin, it is reasonable to give a 300-mg loading dose
of clopidogrel, administered at least 6 hours before
PCI, and/or GP IIb/IIIa antagonists, administered at
the time of PCI. (Level of Evidence: C)
3. When a loading dose of clopidogrel is administered, a
regimen of greater than 300 mg is reasonable to
achieve higher levels of antiplatelet activity more rapidly,
but the efficacy and safety compared with a 300-
mg loading dose are less established. (Level of Evidence: C)
4. It is reasonable that patients undergoing brachytherapy
be given daily clopidogrel 75 mg indefinitely and
daily aspirin 75 to 325 mg indefinitely unless there is
significant risk for bleeding. (Level of Evidence: C)
 
* ''Class IIb''
In patients in whom subacute thrombosis may be catastrophic
or lethal (unprotected left main, bifurcating
left main, or last patent coronary vessel), platelet
aggregation studies may be considered and the dose of
clopidogrel increased to 150 mg per day if less than
50% inhibition of platelet aggregation is demonstrated.
(Level of Evidence: C)
 
==Glycoprotein IIb/IIIa Inhibitors==
 
===Guidelines (DO NOT EDIT)===
* ''Class I''
In patients with UA/NSTEMI undergoing PCI without
clopidogrel administration, a GP IIb/IIIa inhibitor
(abciximab, eptifibatide, or tirofiban) should be
administered. (Level of Evidence: A)*
* ''Class IIa''
1. In patients with UA/NSTEMI undergoing PCI with
clopidogrel administration, it is reasonable to administer
a GP IIb/IIIa inhibitor (abciximab, eptifibatide,
or tirofiban). (Level of Evidence: B)*
2. In patients with STEMI undergoing PCI, it is reasonable
to administer abciximab as early as possible.
(Level of Evidence: B)
3. In patients undergoing elective PCI with stent placement,
it is reasonable to administer a GP IIb/IIIa
inhibitor (abciximab, eptifibatide, or tirofiban). (Level
of Evidence: B)
 
* ''Class IIb''
In patients with STEMI undergoing PCI, treatment
with eptifibatide or tirofiban may be considered.
(Level of Evidence: C)
* *It is acceptable to administer the GP IIb/IIIa inhibitor before performance
of the diagnostic angiogram (“upstream treatment”) or just before
PCI (“in-lab treatment”).
 
==Antithrombotic Therapy: Unfractionated Heparin, Low-Molecular-
Weight Heparin, and Bivalirudin==
 
===Guidelines (DO NOT EDIT)===
* ''Class I''
1. Unfractionated heparin should be administered to
patients undergoing PCI. (Level of Evidence: C)
2. For patients with heparin-induced thrombocytopenia,
it is recommended that bivalirudin or argatroban be
used to replace heparin. (Level of Evidence: B)
* ''Class IIa''
1. It is reasonable to use bivalirudin as an alternative to
unfractionated heparin and glycoprotein IIb/IIIa
antagonists in low-risk patients undergoing elective
PCI. (Level of Evidence: B)
2. Low-molecular-weight heparin is a reasonable alternative
to unfractionated heparin in patients with
UA/NSTEMI undergoing PCI. (Level of Evidence: B)
* ''Class IIb''
Low-molecular-weight heparin may be considered as
an alternative to unfractionated heparin in patients
with STEMI undergoing PCI. (Level of Evidence: B)
 
 
== Surgery and Device Based Therapy ==
'''Acute Results'''
* ''Class I''
It is recommended that distal embolic protection
devices be used when technically feasible in patients
undergoing PCI to saphenous vein grafts. (Level of
Evidence: B)
 
'''Drug-Eluting Stents'''<ref>[http://content.onlinejacc.org/cgi/content/full/j.jacc.2009.10.015]</ref>
* ''Class I''
A drug-eluting stent (DES) should be considered as an
alternative to the bare-metal stent in subsets of
patients in whom trial data suggest efficacy. (Level of
Evidence: A)
* ''Class IIa''
It is reasonable to use a DES as an alternative to a
BMS for primary PCI in STEMI. (Level of
Evidence: B)
* ''Class IIb''
A DES may be considered for clinical and anatomic
settings in which the efficacy/safety profile appears
favorable. (Level of Evidence: B)
 
==ACC/AHA Recommendation for Thrombus Aspiration During PCI(DO NOT EDIT)==
{{cquote|
 
===Class IIa===
1. Aspiration thrombectomy is reasonable for patients undergoing primary PCI .''(Level of Evidence: B)''}}
 
 
 
==References==
{{reflist|2}}
 
== Acknowledgements ==
WikiDoc would like to acknowledge that the verbiage in guidelines recommendations comes from the ACC/AHA guidelines statements.
 
{{Circulatory system pathology}}
{{SIB}}
 
[[Category:DiseaseState]]
[[Category:Cardiology]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 01:33, 20 August 2013

Redirect to:

Retrieved from "https://www.wikidoc.org/index.php?title=Percutaneous_coronary_intervention_(PCI)&oldid=896433"